Navigation Links
Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Date:6/19/2008

SYDNEY, Australia, June 19 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of Bronchitol for bronchiectasis via the Special Protocol Assessment process.

The SPA process allows for FDA evaluation of a clinical trial protocol intended to form the primary basis of an efficacy claim in support of a New Drug Application, and provides an agreement that the study design, including trial size, clinical endpoints and/or data analyses are acceptable to the FDA.

Pharmaxis previously agreed on the trial design with the European regulatory agency (EMEA). This trial will therefore form the basis of a marketing application in both the U.S. and Europe.

The phase 3 trial has been designed in collaboration with internationally renowned experts in the field of bronchiectasis and will be a randomized, placebo controlled, double-blind investigation of Bronchitol twice daily in approximately 350 adults with bronchiectasis. Participants will be treated for 52 weeks and the primary endpoints are reduction in frequency of exacerbations and improvement in quality of life. Secondary endpoints include time to first exacerbation and duration of exacerbation. Additional secondary endpoints are antibiotic use, sputum volume, exercise tolerance and lung function measurements. The trial includes health economic analysis and will be conducted in centers across Europe and the U.S.

This trial is the second Phase III study to be undertaken for Bronchitol in bronchiectasis and follows the completion of a successful shorter trial reported last year.

Pharmaxis CEO, Alan Robertson, said the company was pleased to have concluded its discussions with the FDA and the EMEA.

''We believe this phase 3 trial design will allow us to thoroughly demonstrate the clinical benefits of Bronchitol in a patient populat
'/>"/>

SOURCE Pharmaxis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Establishes Named Patient Program for Bronchitol
2. Pharmaxis Long-Term Safety Study of Bronchitol Completes
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
5. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
6. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
9. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
10. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
11. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 Discovery Laboratories, Inc. ... focused on developing aerosolized KL4 surfactant therapies for ... webcast at 8:30 a.m. Eastern Time on Tuesday August ... the 2015 second quarter financial results along with ... a press release announcing the second quarter 2015 ...
(Date:8/3/2015)... Ill. , Aug. 3, 2015 Your ... problem, and you,re looking for the best possible outcome. ... the best outcome too, and now there,s a ... Following steps recommended by the American Orthopaedic Foot ... surgery can help you avoid complications and heal as ...
(Date:8/3/2015)...  Sage Analytics ( www.sageanalytics.com ), the developers of ... systems, announced its sponsorship of the California Cannabis Industry ... number of tickets are available for groups or individuals ... while enjoying an open bar, buffet dinner and hors ... Bay at sunset. With the legislative session ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2Patient Guide: How to Prepare for Surgery 2Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2
(Date:8/3/2015)... ... 2015 , ... The Workgroup for Electronic Data Interchange ( WEDI ), the ... healthcare information exchange, announced the release of its findings from its June 2015 ICD-10 ... WEDI shared survey results and recommendations , strongly encouraging the department ...
(Date:8/3/2015)... ... August 03, 2015 , ... Kantor & Kantor, LLP announced ... firm’s client Rebecca Hamsher, deciding that in accordance with ERISA ( Employee Retirement ... residential treatment for bulimia, depression and other mental health problems. , According to ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent ... overwhelming number of Hispanics believe people can positively affect their diabetes, few look ... queried said making diet changes was important. Far fewer participants mentioned the need ...
(Date:8/3/2015)... ... 03, 2015 , ... Novatus, Inc. today launched the largest ... well as announced the date of its next major release. , Version 6.0 ... tasks as well as enhancements to the customer experience. Users now enjoy ...
(Date:8/3/2015)... ... August 03, 2015 , ... It’s ... Ahjumawi Lava Springs, California’s northernmost and among its least visited State Parks. The ... aquifers, whose main outflow is at Ahjumawi Lava Springs, part of the Fall ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Novatus Unveils Milestone Software Release 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4
... stroke a major issue in analysis of 33 research projects ... 33 studies on drugs known as beta blockers has concluded ... than heart surgery. In fact, using beta blockers for non-coronary ... say. , The researchers who conducted the study -- known ...
... bypass does not cause short-term neurological problems in ... heart defects, according to pediatric researchers. The new ... adverse neurological effects after newborn surgery for more ... for school-aged children who receive surgery for these ...
... WASHINGTON, Nov. 10 A Guide to Implementing,GASB 45, a ... Government,Excellence, examines how North Carolina local governments are meeting their,obligations ... issue brief, which is based on a survey of the ... $100 million, reports that:, -- 88 percent ...
... -- Net Revenue Increased 93.6% to US$146.5 million; Non-GAAP Gross Margins ... ... Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: MR ), ... its selected,unaudited financial results for the third quarter and nine months ...
... (Amex: IMM ) today announced results for its ... three months ended September 30, 2008, revenues were $506,000,as ... 30, 2007.,The decrease was primarily attributable to revenues from ... three months ended,September 30, 2008 was $2,446,000, as compared ...
... leads to more bleeding, longer hospital stay, study finds , , ... the clot-preventing drug Plavix less than five days before having ... more likely to require a second operation, and will spend ... current guidelines. , Those guidelines from the American College of ...
Cached Medicine News:Health News:Beta Blocker Use Questioned in Non-Heart Surgery 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 3Health News:No drop in IQ seen after bypass for child heart surgery 2Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 2Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 3Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 4Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 5Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 6Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 7Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 8Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 9Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 10Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 11Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 12Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 13Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 14Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 15Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 16Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 17Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 18Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 19Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 20Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 21Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 22Health News:Mindray Announces 2008 Third Quarter and Nine Months Results 23Health News:Immtech Reports Fiscal Second Quarter 2009 Results 2Health News:Immtech Reports Fiscal Second Quarter 2009 Results 3Health News:Study Upholds Stopping Plavix Use Before Surgery 2
Double cuff electronic tourniquet....
... Safety. Convenience. Reliability. Cost. These are ... OR personnel, and administrators. With a special ... most practical elements of todays technology to ... , The A.T.S. 2000 Tourniquet uses ambient ...
... a revolutionary new addition to the Hall® ... PowerPro Battery System is the first and ... on the market. It is a full-function ... the requirements of large bone, small bone, ...
Stryker Instruments, the leader in cordless power, advances orthopaedics with the power, speed, versatility, reliability and performance through its heavy duty powered instruments....
Medicine Products: